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Abstract The problems of new psychoactive substances
(NPSs), especially related to drivers, constitute an open
research area. In this case report, we present a traffic
accident case, in which two passengers of five individuals
died instantly, while the other three persons survived the
accident with minor injuries only. From the blood samples
of the driver and the passengers, a-pyrrolidinovalerophe-
none (a-PVP), an NPS belonging to the category of
cathinone derivatives, was disclosed. Therefore, we
established a detailed procedure for analysis of a-PVP in
blood samples by liquid chromatography–tandem mass
spectrometry. After careful validation tests of this method,
a-PVP concentration in blood samples from the surviving
driver and passengers, and from the two deceased, were
measured. The concentrations varied from 20 to 650 ng/
mL. Access to detailed information originating from the
court files and from explanations provided by the driver
and eye witnesses revealed extremely valuable illustrative
details addressing the symptoms and pharmacological
effects of a-PVP on the human organism, thus contributing
to enriching the body of knowledge of a-PVP abuse.
Keywords Traffic accident  New psychoactive
substances (NPSs)  a-pyrrolidinovalerophenone (a-PVP) 
Psychological symptoms  DRUID
Introduction
The issues associated with driving under the influence of
alcohol and narcotic substances are subject to continuous
interest not only for legal practitioners, but also for the
police, prosecution, and medico-legal teams. Among ini-
tiatives implemented in this field, there is the European
Union DRUID program carried out by 19 EU countries in
the years 2006–2011, aiming at evaluating the phenomena.
The final report claimed that although the gravest danger in
traffic in EU member countries was posed by alcohol
consumption, especially when combined with medications,
considerable problems also arose by other psychoactive
substances, such as amphetamines and cannabis that are the
most popular [1].
Practice shows that preliminary testing of a driver by
police road patrol to detect the presence of alcohol and
classic narcotic substances often yields a negative result;
the driver may be under the influence of other psychoactive
agent(s), the presence of which is not detected by most of
testers. This may cause the driver to develop a sense of
impunity and thus leads to increased chance of traffic
accidents. Inasmuch as the issue of alcohol and classic
narcotic substances in relation to traffic has been legally
regulated in keeping with legislative directives of particular
European countries, the problem of new psychoactive
substances (NPSs) as related to drivers constitutes an open
research area. Although research papers addressing this
subject have been published [2–6], the problem continues
to be poorly investigated.
In this case report, we present a traffic accident case in
which two passengers were killed, and the driver and
two passengers survived; from the blood samples of all
individuals, variable concentrations of a-pyrrolidino-
valerophenone (a-PVP), an NPS belonging to the category
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of cathinone derivatives, were detected. Access to detailed
information originating from the court files and derived
from explanations provided by the driver and the eye
witnesses revealed extremely valuable illustrative material
addressing the effect of a-PVP on the human organism,
thus contributing to enriching the body of knowledge of the
NPS.
Case history
According to the court files, in a small town in Poland, a
group of young people was driving home from a nearby
discotheque in early morning hours. Approximately at
6 a.m. the driver, exercising no special caution, drove
onto the curb of a safety island, lost control of the car,
and drove into a ditch, where the car overturned and hit a
tree. In consequence of the accident, two passengers, a
17-year-old female and a 28-year-old male, were killed
instantly; one of the remaining passengers, a 19-year-old
female, suffered a minor spine injury, while another
passenger, a 36-year-old male, and the 21-year-old driver
succumbed to minor injuries. Immediately upon arrival of
the police, the surviving individuals involved in the
accident, the driver and the passenger sitting in front were
tested for state of intoxication by means of breath ana-
lyzers. The wounded female passenger was tested upon
arrival at a hospital *1 h later, while the deceased
individuals were tested by means of postmortem blood
analysis. After the accident, blood samples were collected
and analyzed for psychoactive substances, with the
exception of the injured 19-year-old female, whose blood
was tested for ethyl alcohol upon admission. As follows
from the court files, all people involved in the accident
except the driver were under the influence of alcohol,
which was later confirmed by tests.
The sensations felt by the driver following his taking the
narcotic substance were described on his allegation. The
psychoactive substance was insufflated through the nose by
him and his friends. They had a form of crystals called
FETA, KATAR, or KRYSTYNA. The persons attending
the party had taken the first fix of the psychoactive sub-
stance *6 h prior to the accident. The driver informed that
the fix of the substance in an amount of *0.4 g ‘‘was
good’’ for about 6 h. One person had prepared the so-called
toot, which was then divided and insufflated through the
nose. The doses were not calculated, but rather applied
using a ‘‘hit-and-miss’’ method. Having insufflated the first
fix of the substance, the driver felt agitated, started to sweat
profusely, and experienced palpitations. He exploded with
energy in spite of the fact that he was tired, having pre-
viously performed physical labor in the forest. He had not
taken any alcohol. Together with his friends, he took
another fix 4 h later, i.e., *2 h prior to the accident.
Afterwards, he was agitated, no longer sleepy, and did not
experience palpitations or sweating; he was only thirsty,
but generally felt well and full of inner energy. Immedi-
ately before the accident, however, he recounted: ‘‘…sud-
denly I saw spots before my eyes…for a moment I felt as if
I had lost consciousness, when I snapped out, there was a
safety island in front of me…then I jerked the steering
wheel to the right and to the left…. I put the car in neu-
tral…I pressed the gas and clutch…I did not use brakes…I
could not control the car…’’. Then everything went very
fast. The car overturned. The passengers sitting in the
backseat occupying side seats, without their seat-belts
fastened, died instantly, the remaining individuals sus-
tained minor injuries.
It was obvious that the driver and the fault that he
committed would be burdened by the highest degree of
guilt for causing the accident; nevertheless, according to
the information available, the other individuals present in
the car and involved in the accident might contribute to its
happening indirectly. At the discotheque, through various
forms of pressure, the driver was forced by the other par-
ticipants to drive, because he had not drunk alcohol.
However, he did not have a driving license. During the
drive, the passengers were agitated, and they shouted to
pressure the driver into going faster.
Addressing a question to experts whether the presence
of a-PVP at the level determined could have affected the
psychomotor abilities of the driver leading to the miserable
accident, the public prosecutor’s office expected a justified
and positive answer.
It should be added that the two passengers sitting in the
backseat died at the place of the event. According to the
available data, the cause of death of both individuals was
severe multiorgan damage; moreover, the 17-year-old
female sustained a spinal fracture, and the 28-year-old
male had a fracture of the skull base.
Materials and methods
Biological materials
Sample of peripheral blood was collected from the driver
and from two living passengers after accident. Autopsy
blood was also taken from two dead victims during autopsy
carried out within 24 h after death. The samples were kept
frozen (-20 C) until analyses. Blank blood samples for
development and validation of analytical method were
taken from unpoisoned subjects and from the Regional
Centre of Blood Donation and Blood Treatment in Kraków.
404 Forensic Toxicol (2016) 34:403–410
123
Standards and chemicals
Standard solutions of 1-(4-methoxyphenyl) piperazine (4-
MeOPP), 1-(m-trifluoromethylphenyl) piperazine
(TFMPP), 1-benzylpiperazine (BZP), 1-methyl-4-(phenyl-
methyl)-piperazine (MPMP), 2,5-dimethoxy-4-methylam-
phetamine (DOM), 2-methylmethcathinone (2-MMC), 3,4-
dimethylmethcatinone (3,4-DMMC), 3,4-methylene-
dioxyamphetamine (MDA), 3,4-methylenedioxyethylam-
phetamine (MDEA), 3,4-methylenedioxymethyl-
amphetamine (MDMA), 3,4-methylenedioxypyrovalerone
(MDPV), 3,4-methylenedioxy-a-pyrrolidinobutiophenone
(MDPBP), 3-methylmethcathinone (3-MMC), 4-bromo-
2,5-dimethoxyamphetamine (DOB), 4-bromo-2,5-
dimethoxyphenethylamine (2C-B), 4-chloromethcathinone,
4-fluoroamphetamine, 4-hydroxymethamphetamine,
4-methoxyamphetamine (PMA), 4-methoxymetham-
phetamine (PMMA), 40-methoxy-a-pyrrolidinopropiophe-
none (MeOPPP), 4-methylethcathinone (4-MEC),
4-methylmethcathinone (4-MMC, mephedrone), 5-(2-
aminopropyl) benzofuran (5-APB), 5-(2-ethylaminopropyl)
benzofuran (5-EAPB), 5-(2-methylaminopropyl) benzofu-
ran (5-MAPB), 6-(2-aminopropyl) benzofuran (6-APB),
amphetamine, brephedrone, buphedrone, butylone, caf-
feine, cathinone, ephedrine, ephedrone, ethylphenidate,
flephedrone, methamphetamine, methcathinone, methyl-
benzylpiperazine, methylone, methylphenidate, N,N-
dimethylamylamine, naphyrone, N-ethylbuphedrone
(NEB), N-ethylcathinone, N-methyl-1,3-benzodioxolylbu-
tanamine (MBDB), pentedrone, phentermine, phenyl-
propanolamine (norepherdrine), pseudoephedrine, a-PVP,
and a-PVP-d8 used as internal standard (IS), were pur-
chased from LGC Standards (Łomianki, Poland); ammo-
nium formate, ammonium carbonate, formic acid, and
acetic acid (all C99.9 % for LC-MS) from Sigma (Poznań,
Poland); acetonitrile, methanol (all C99.9 % for LC–MS)
and solid-phase extraction (SPE) columns LiChrolut RP-18
containing 500 mg C18-RP bonded silica from Merck
(Warszawa, Poland).
Extraction procedure
Each 1-mL sample was put into a clean 15-mL tube and
diluted with 0.01 M carbonate buffer to pH 9.3 (1:5, v/v).
a-PVP-d8 at a concentration of 0.1 mg/L was added to each
sample. Then, the samples were vortexed and centrifuged
for 7.5 min at 44009g.
The SPE cartridge was firstly equilibrated with 1 mL
each of methanol, distilled water, and the above carbonate
buffer pH 9.3, and then the supernatant of each blood
sample was applied on the cartridge and slowly passed
through it. In the next step, matrix impurities were cleaned
with 2 mL of the carbonate buffer pH 9.3, and then vacuum
was applied to each cartridge for 30 min to remove residual
moisture. The analytes were eluted with 2 mL of the 1 M
acetic acid in methanol (1:9, v/v). The eluate was evapo-
rated to dryness under a gentle nitrogen stream at 40 C,
and the residue was dissolved in 0.1 mL of a mixture of
mobile phases (95 % phase A ? 5 % phase B) and injected
into a liquid chromatography–tandem mass spectrometry
(LC–MS-MS) system.
The calibrators for quantitative analysis were prepared
by spiking a-PVP (0.010, 0.025, 0.050, 0.250, and
0.500 mg/L) into the drug-free blood prior to extraction.
Instrumentation
Liquid chromatography
An Agilent Technologies 1200 liquid chromatograph
(Santa Clara, CA, USA) equipped with a binary pump
(G1312 A) and an autosampler (G1329 A) was used. A
0.01 mL injection loop was used in the gradient mode. The
chromatographic separation was performed with a Poro-
shell 120 EC-C18 column (100 9 3.0 mm id, particle size
2.7 lm, Agilent Technologies) and a Poroshell 120 EC-
C18 guard column (5 9 3.0 mm id, Agilent Technologies).
The phase A was water, which contained 0.2 % formic acid
and 0.002 M of ammonium formate, and the phase B was
acetonitrile with 0.2 % formic acid and 0.002 M of
ammonium formate.
The gradient for samples concerning a-PVP and IS was
programmed as follows: 95 %A/5 %B at a flow rate of
0.5 mL/min, followed by a linear change to 5 %A/95 %B
at a flow rate of 1 mL/min in 10 min and held for 5 min.
Tandem mass spectrometry
A 6410 triple quadrupole mass spectrometer (Agilent
Technologies) equipped with an electrospray ionization
(ESI) source, operated under the positive mode was used.
The operational parameters of the ESI source were as
follows: vaporizing temperature, 350 8C; pressure of the
nebulising gas, 40 psi; flow of the drying gas, 9 L/min;
capillary potential, 3.5 kV; fragmentor voltages, 84 V for
a-PVP and 99 V for a-PVP-d8. The mass spectrometer was
operated in the multiple reaction monitoring (MRM) mode
with the transitions at m/z 232.1/91.1 (quantification) and
232.1/77.1 (qualification) for a-PVP and at m/z 240.3/91.1
and 240.3/77.1 for a-PVP-d8, respectively. The optimized
collision-induced dissociation (CID) energies were 25 eV
for transitions at m/z 232.1/91.1 (a-PVP) and at m/z 240.3/
91.1 (a-PVP-d8), and 53 eV for transitions at m/z 232.1/
77.1 (a-PVP) and at m/z 240.3/77.1 (a-PVP-d8).
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Validation of the LC–ESI-MS-MS method
Selectivity
To evaluate peak-purity and selectivity, blank blood sam-
ples (neither analyte nor IS added) were analyzed with each
batch to check for impurity peaks that might interfere with
detection of a-PVP or IS. To assess possible interferences
of a-PVP, quality control (QC) samples were spiked indi-
vidually to contain 10 mg/L each of 4-MeOPP, TFMPP,
BZP, MPMP, DOM, 2-MMC, 3,4-DMMC, MDA, MDEA,
MDMA, MDPV, MDPBP, 3-MMC, DOB, 2C-B,
4-chloromethcathinone, 4-fluoroamphetamine, 4-hydrox-
ymethamphetamine, PMA, PMMA, MeOPPP, 4-MEC,
4-MMC, 5-APB, 5-EAPB, 5-MAPB, 6-APB, ampheta-
mine, brephedrone, buphedrone, butylone, caffeine, cathi-
none, ephedrine, ephedrone, ethylphenidate, flephedrone,
methamphetamine, methcathinone, methylbenzylpiper-
azine, methylone, methylphenidate, N,N-dimethylamy-
lamine, naphyrone, NEB, N-ethylcathinone, MBDB,
pentedrone, phentermine, phenylpropanolamine
(norepherdrine), and pseudoephedrine.
Linearity and limits of quantification and detection
Calibration curves were constructed after the analysis of
drug-free blood sample containing known amounts of a-
PVP. To prepare these standards, blood samples were spiked
with a-PVP at the following concentrations: 0.010, 0.025,
0.050, 0.250, and 0.500 mg/L. Each level was prepared in
triplicate. The samples were extracted according to the
procedure described before. Calibration curves were con-
structed by plotting the peak-area ratios (y) of the analyte (a-
PVP)/(a-PVP-d8) against a-PVP concentration (x).
Validation samples were prepared in triplicate at the
following concentrations: 0.020, 0.100, 0.500 mg/L of a-
PVP to assess the accuracy of the method. Negative QC
samples were analyzed after each linearity sample to
evaluate potential carry-over. The limit of detection (LOD)
of the method was determined by analyzing validation
samples (n = 5) to determine if acceptance criteria were
met for the analyte. The LOD was defined as the lowest
concentration at which the analyte ion signal-to-noise ratio
(determined by peak area) was C10. The limit of quan-
tification (LOQ) was defined as the lowest concentration
that met LOD criteria and also had a standard deviation
within ±20 %.
Accuracy and precision
Inter- and intra-assay accuracy and precision data for a-
PVP were determined with the low (0.020 mg/L), medium
(0.100 mg/L), and high (0.500 mg/L) QC samples. Intra-
assay data were assessed by comparing data from within
one run (n = 5) and inter-assay data were determined with
five separate runs (n = 15). Data were evaluated using
one-way analysis of variance with day as the grouping
variable. Accuracy, expressed as a percentage, was calcu-
lated by dividing the mean calculated concentration by the
spiked concentrations, and multiplying by 100. Precision,
expressed as percent relative standard deviation (%RSD),
was determined by calculating the percent ratio of the
standard deviation divided by the calculated mean con-
centration and multiplied by 100.
Matrix effect, extraction efficiency, and process efficiency
Extraction efficiency, matrix effect and process efficiency
were evaluated via three sets of samples as described by
Matuszewski [7]. Extraction efficiencies for a-PVP and IS
were measured at each QC concentration. Blank blood was
fortified with a-PVP and IS solution before and after SPE.
Percent extraction efficiency from blood was expressed as
mean analyte area of QC samples (n = 5) fortified with
references standard solution before extraction divided by
mean area of samples (n = 5) with references standard
solution added after SPE. The matrix effect (relative) was
calculated by comparing analyte peak areas obtained from
six different blank blood samples fortified with a-PVP and
IS solutions after SPE with peak areas of references stan-
dards solution at the same nominal concentrations prepared
in a 95:5 (v/v) mixture of mobile phases A and B (neat
samples). Matrix suppression or enhancement (absolute
matrix effect) was calculated as follows: (mean peak area
of fortified blood after SPE/mean peak area of the neat
sample) 9 100 - 100. The process efficiency shows the
overall effect of SPE extraction efficiency and matrix effect
on the quantification of analytes of interest. This was
determined by comparing the mean analyte peak area of
five samples fortified before SPE with the mean peak area
of five neat samples prepared in the mobile phase.
Stability
Processed sample stability was investigated by reinjecting
low, medium, and high QC extracted samples stored at 4 C
for 24, 48, and 72 h on the autosampler (n = 3) and at room
temperature for 72 h and by calculating the results against
the original calibration curve as a percent differences.
Results
In the present study, we experienced five people who were
involved in a traffic accident; among them, two were killed
and three were injured, but survived the accident. It was
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disclosed that all of them had taken the NPS a-PVP. To
accurately quantify a-PVP in their blood samples, we have
established a detailed procedure for its analysis by LC–
ESI-MS-MS together with the validation of the method.
First of all, we tested the selectivity of this method using
more than 50 of psychoactive compounds, but none of
them interfered with the peck of a-PVP or IS (Fig. 1). The
linearity of the calibration curve was confirmed in the
range of 0.010–0.500 mg/L for a-PVP in blood samples;
the regression equation and correlation coefficient r were :
y = 0.0062x - 0.047, and r = 0.9994, respectively. The
LOD and LOQ were 0.005 and 0.010 mg/L, respectively.
Accuracy and precision data were generally satisfactory
(Table 1).
Because we used stable isotopic a-PVP as IS (isotope
dilution method), it seems not necessary to present matrix
effects and efficiencies. However, the data seem to be of
interest for readers. The results showed that the method
suffered from appreciable suppressive matrix effects
(Table 2).
The stability of a-PVP at 4 C and room temperature
showed that this compound is relatively stable (Table 3).
In blood samples collected from the surviving and
deceased participants in the accident, the analysis demon-
strated a-PVP in a diversified range of concentration values.
The results of toxicological tests performed in individuals
involved in the accident are presented in Table 4.
The blood samples were collected from the driver 3.5
and 4.5 h after the accident, arriving at an increasing
sequence of a-PVP concentration values of 230 and
360 ng/mL, respectively. As it follows from data origi-
nating from the court records, the male insufflated the
psychoactive twice in the period preceding the accident,
i.e., *6 and 2 h previously, which explains the results as
the effect of interposition of the elimination and absorption
phases of both doses taken at different times. The
demonstrated concentrations of a-PVP in the blood of the
driver should be considered high as compared with the
literature data available [4, 8]. It may be also assumed that
at the time of the accident, the blood a-PVP level of the
Fig. 1 Multiple reaction monitoring chromatograms and product ion mass spectra of a-PVP (top) and a-PVP-d8 (bottom) extracted from an
autopsy blood sample of passenger 3 recorded by liquid chromatography–electrospray ionization-tandem mass spectrometry
Table 1 Accuracy and
precision data of the developed
method
Concentration of a-PVP (mg/L) Intra-assay (n = 5) Inter-assay (n = 15)
Accuracy
(%)
Precision
(%RSD)
Accuracy
(%)
Precision
(%RSD)
0.020 16.7 2.9 10.2 3.5
0.100 -0.8 3.0 -6.5 7.1
0.500 1.2 1.0 -0.9 1.8
RSD relative standard deviation
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driver might have been higher than the level demonstrated
in the tests. Passenger 1, a survivor of the accident, had
taken a-PVP *7.5 and 13.5 h before blood collection, and
after that period, the substance continued to be present in
his blood at 30 and 20 ng/mL, respectively. On the other
hand, in the blood of the deceased individuals involved in
the accident, a-PVP concentration values were high (650
and 290 ng/mL), because they reflected the levels of the
drug after 6 and 2 h after insufflating a-PVP doses. The
numerical values were different, which most likely resulted
from the difference in the size of doses apportioned to both
abusers using the ‘‘hit-and-miss’’ method and in their body
parameters.
Discussion
In the analyzed case, chemical and toxicological tests
demonstrated a psychoactive substance a-PVP in the blood
samples collected from the driver and perpetrators of the
accident. The alleged substance belongs to the group of
NPSs, being in the category of synthetic cathinone
derivatives. Until 2015, a-PVP was not included in the list
of narcotic substances and psychotropic agents of the legal
regulations in force [9]. The cathinone a-PVP belongs to
the group of pyrrolidinophenones. The group also includes
two structural a-PVP analogues, namely pyrovalerone and
MDPV, which are included in the list of psychotropic
substances in the above regulation.
Although a-PVP was synthesized in the 1960s, at the
present time it has gained some popularity in the narcotic
market. Among various types of cathinones, derivatives of
a-PVP have become popular as NPSs due to the presence
of the lipophilic pyrrolidinyl group that increases the
ability to cross the blood-brain barrier to obtain a better
psychedelic effect [10, 11].
The mechanism underlying a-PVP activities is poorly
understood, and for this reason, while commenting on the
biological activities of the compound, the likeness of its
activities to those of other compounds is also taken into
consideration, namely pyrovalerone and especially MDPV,
which show close similarity in their chemical structures
and allow assuming that they may be similar to their bio-
logical activities. Generally, all three above-mentioned
compounds belong to selective reuptake inhibitors of
neurotransmitters dopamine, noradrenaline, and serotonin.
In view of their mechanism of activity, pyrrolidinophe-
nones are considered central nervous system stimulants. As
a rule, the basic anticipated symptoms of people often
taking the above compounds include enhanced energy,
euphoria, empathy, openness, and increased libido. Nev-
ertheless, soon afterwards, there may appear such negative
side effects as tachycardia, increased arterial pressure,
confusion, agitation, insomnia, aggression, and hallucina-
tions [4].
The employed a-PVP doses have not been precisely
determined. However, based on the presently analyzed case
and data derived from Internet forums frequented by young
people, there may be a fairly broad range of 100–500 mg.
The available literature described that as compared to
cocaine and amphetamine, which belong to the group of
classic central nervous system stimulants, both a-PVP and
its structurally close derivative MDPV are much more
potent selective reuptake inhibitors of dopamine and
Table 2 Matrix effects, extraction efficiencies, and process efficiencies of the developed method
Compound Blood
concentration
(mg/L)
Matrix effect (%) Coefficient of
variation (%RSD)
Extraction
efficiency
(%)
Process
efficiency
(%)Relative Absolute suppression/enhancement
a-PVP 0.020 0.24–0.36 -75.8 to -63.3 6.7 17.5–44.9 6.3–15.1
0.100 0.25–0.35 -74.7 to -64.8 5.6 26.4–84.6 8.1–21.4
0.500 0.31–0.35 -68.8 to -64.8 2.2 57.4–77.1 19.4–25.9
a-PVP-d8 0.100 0.33–0.45 -67.5 to -54.7 7.7 31.0–87.0 11.8–28.3
Table 3 Stability of a-PVP
Compound Blood concentration
(mg/L)
Percent difference
4 C Room temperature
24 h 48 h 72 h 72 h
a-PVP 0.020 -0.16 -7.0 11.9 6.8
0.100 -2.1 -11.5 11.6 11.5
0.500 -0.48 -2.6 14.0 12.5
a-PVP-d8 0.100 -3.9 -8.3 11.5 5.7
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noradrenaline. Moreover, in studies performed in mice, a
significant increase in locomotor activity by the com-
pounds was demonstrated, being higher than that by
cocaine and amphetamine and resulting from an increased
dopamine level [12]. Psychophysical tests employed in
assessment of ability to operate motor vehicles and per-
formed in individuals under the influence of MDPV
demonstrated considerable functional impairment of psy-
chomotor abilities in 84 % of testees, and in 7 %, there was
moderate or complete inability to operate motor vehicles.
The determined blood MDPV concentration values in the
tested individuals were below 500 ng/mL [12]. In view of a
lack of data on toxic a-PVP levels, interpretation of toxi-
cology results in the analyzed case is most assuredly
complex and ambiguous.
Knoy et al. [4] described a case of a driver under the
influence of a-PVP. The driver was stopped by the police
due to bravado driving; following the intervention, the
policemen noticed symptoms that might suggest his being
under the influence of a narcotic substance, namely verbal
confusion, disorientation, excitation, tachycardia, dilated
pupils, and tremors. The symptoms observed in the course
of the above police intervention are similar to those pre-
viously noted in cases of other representatives of the
pyrrolidinophenone group. During subsequent procedures
involving the above driver, his blood sample collected
*2 h after the police intervention demonstrated a-PVP at
a concentration of 63 ng/mL, being thus several times
lower than the values noted in the presently analyzed driver
case (a-PVP 230 and 360 ng/mL).
Analyzing possible behavior patterns of individuals
under the influence of a-PVP, one may also quote other
cases that well illustrate the patterns, although they are not
related to traffic. Nagai et al. [8] provide a description of a
male who exhibited sudden violent behavior at a place
where several individuals lived together. The roommates
tried to restrain the excited man, who collapsed after
approximately 2 h of struggling, and after 30 min of rou-
tine resuscitation efforts, he died. His restraint was thought
to induce death from asphyxia due to chest compression.
During autopsy, intra-neck muscle hemorrhage, submental
and high neck petechiae, and facial congestion were
observed. Toxicological analysis of a postmortem blood
sample demonstrated 411 ng/mL of a-PVP.
The present authors experienced a case of a death of a
19-year-old man with an underlying mechanism similar to
that described above [13]. Because of his aggressive and
dangerous behavior, the man was brought to a mental
hospital by the police. In the hospital, following a short
period of calming down, he developed progressive motor
agitation and started to destroy a patient room, and it was
necessary to restrain him using immobilization belts. In
spite of intense efforts at resuscitation, the patient died of
acute circulatory and respiratory failure associated with
psychomotor excitation. A postmortem blood sample
showed a-PVP at the level of 850 ng/mL.
In both above cases, the mechanism of death should be
considered within the category of complications of patho-
logical motor excitation. The mechanism is most commonly
encountered in individuals who are incapable of controlling
their behavior, being under the influence of psychoactive
substances or exhibiting alcohol delirium. Pathological
excitation causes the affected individual to thrash around
purposelessly, chaotically employing all muscles at the same
time, which markedly intensifies oxygen consumption.
Nagai et al. [8] drew attention to the danger of
employing sustained restraint of excited persons with hal-
lucinations resulting from a-PVP or other stimulants,
suggesting the use of sedation and adrenergic blockade.
Thus, as it follows from the practice of the present authors
Table 4 Toxicology results of
the participants in the accident
Individual Blood collection
time
Concentration
of a-PVP
(ng/mL)
Time Post-accident
alcohol blood level
(%)
Living subjects
Driver, male—21 years 9:30 a.m.
10:30 a.m.
230
360
6:45
a.m.
0.0
Passenger 1, male—36 years,
front seat
10:10 a.m.
01:30 p.m.
30
20
6:50
a.m.
1.2
Passenger 2, female—19 years,
back seat, center
–a –a 7:10
a.m.
0.4 (medical
records)
Autopsy subjects
Passenger 3, female—17 years
back seat, side
– 650 – 1.9
Passenger 4, male—28 years
back seat, side
– 290 – 2.6
a Not sampled
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[13] and published literature data [8], as compared to
methamphetamine and MDMA, which can be lethal, a-
PVP and related drugs appear to be less lethal, but seem
more hallucinogenic and agitating.
The metabolism of a-PVP may be fairly slow. Such a
thesis results from observations of its concentration values
demonstrated for example in the blood of the participants
in the traffic accident. As shown in Table 4, in the sur-
viving passenger 1, the compound (20 ng/mL) was detec-
ted, even 13.5 h after his having taken the last dose.
Analyzing the available court records pertaining to the
present case, including the driver’s medical and psycho-
logical examination results, there is no doubt that at the
time of the accident, he might have lost normal psy-
chomotor ability resulting in increased energy and eupho-
ria, and might have been agitated and unable to control his
car fully; he also might have had a brief episode of
unconsciousness. Moreover, the behaviors of the passen-
gers who were also under the influence of the drug might
have influenced the decreased alertness of the driver while
driving a car. The very well-documented description of the
behavior of the driver accused of causing a traffic accident,
being under the influence of a-PVP and being based mainly
on the explanations that he provided is in accordance with
the classic features of the substance effects observed in
other individuals and described in the literature. Addi-
tionally, attention was focused on the mental aspect of the
analyzed case, which cannot be unrelated to the tragic
accident.
Conclusions
The presented case report points to a unique opportunity to
understand the psychological effects of a-PVP in a real
driving situation, emphasizing—along with another report
[4]—the importance of police observation on the road,
especially when alcohol and/or classic narcotic substances
have been ruled out at the site.
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